Economic burden of systemic lupus erythematosus flares and comorbidities in a commercially insured population in the United States

Journal of Occupational and Environmental Medicine

Volumn 55, Issue 11, 2013, Pages 1262-1270

  Narayanan, Siva ^a   Wilson, Kathleen ^b   Ogelsby, Alan ^c   Juneau, Paul ^b   Durden, Emily ^b  

^a Ipsos   (United States)

^b IBM WATSON HEALTH   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ABSENTEEISM; ADULT; ARTICLE; COMORBIDITY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; COST OF ILLNESS; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH MAINTENANCE ORGANIZATION; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PREFERRED PROVIDER ORGANIZATION; SYSTEMIC LUPUS ERYTHEMATOSUS; UNITED STATES; WORK DISABILITY;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; COMORBIDITY; COST OF ILLNESS; FEMALE; HEALTH CARE COSTS; HEALTH EXPENDITURES; HUMANS; INSURANCE, HEALTH; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SICK LEAVE; UNITED STATES; YOUNG ADULT;

EID: 84888111559     PISSN: 10762752     EISSN: 15365948     Source Type: Journal    
DOI: 10.1097/JOM.0000000000000008     Document Type: Article

References (39)

1. Lupus Foundation of America. Understanding lupus. Available at http://www. lupus.org. Accessed July 15, 2011
2. Nichol MB, Shi S, Knight TK,Wallace DJ,Weisman MH. Eligibility, utilization, and costs in a California Medicaid lupus population. Arthritis Rheum. 2004;51:996-1003 (Pubitemid 39648194)
3. Sule S, Petri M. Socioeconomic status in systemic lupus erythematosus. Lupus. 2006;15:720-723
4. Crosslin KL, Wiginton KL. The impact of race and ethnicity on disease severity in systemic lupus erythematosus. Ethn Dis. 2009;19:301-307
5. Petri S, Singh S, Tesfasyone H, Malik A. Prevalence of flare and influence of demographic and serologic factors on flare risk in systemic lupus erythematosus: a prospective study. J Rheumatol. 2009;36:2476-2480
6. Buyon JP, Petri MA, Kim MY, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med. 2005;142: 953-962
7. Carls G, Li T, Panopalis P, et al. Direct and indirect costs to employers of patients with systemic lupus erythematosus with and without nephritis. J Occup Environ Med. 2009;51:66-79
8. Silverman S, Dukes EM, Johnston SS, Brandenburg NA, Sadosky A, Huse DM. The economic burden of fibromyalgia: comparative analysis with rheumatoid arthritis. Curr Med Res Opin. 2009;25:829-840
9. Gibson TB, Ng E, Ozminkowski RJ, et al. The direct and indirect cost burden of Crohns disease and ulcerative colitis. JOccup Environ Med. 2008;50:1261-1272
10. Ward MM. Access to care and the incidence of end-stage renal disease due to systemic lupus erythematosus. J Rheumatology. 2010;37:1158-1163
11. Pelletier EM, Ogale S, Yu E, Brunetta P, Garg J. Economic outcomes in patients with systemic lupus erythematosus with or without nephritis: results from an analysis of data from a US claims database. Clin Ther. 2009;31:2653-2664
12. Li T, Carls GS, Panopalis P, Wang S, Gibson TB, Goetzel RZ. Long-term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: a five-year analysis of a large Medicaid population. Arthritis Rheum. 2009;61:755-763
13. Kozora E, Ellison MC,West S.Depression, fatigue, and pain in systemic lupus erythematosus (SLE): relationship to the American College of Rheumatology SLE neuropsychological battery. Arthritis Rheum. 2006;55:628-635 (Pubitemid 44289884)
14. Partridge AJ, Karlson EW, Daltroy LH, et al. Risk factors for early work disability in systemic lupus erythematosus: results from a multicenter study. Arthritis Rheum. 1997;40:2199-2206 (Pubitemid 28016416)
15. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383 (Pubitemid 17055592)
16. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993;46:1075-1079
17. Lupus Foundation of America. Flares, and what triggers lupus. Available at http://www.lupus.org/webmodules/webarticlesnet/templates/ new aboutintroduction.aspx?articleid=76&zoneid=9. Accessed February 24, 2009
18. Gordon C, Sutcliffe N, Skan J, Stoll T, Isenberg DA. Definition and treatment of lupus flares measured by the BILAG index. Rheumatology. 2003;42:1372-1379 (Pubitemid 37407029)
19. Garris C, Jhingran P, Engel-Nitz NM, et al. Assessing systematic lupus erythematosus disease severity and disease flares: development of a claims-based algorithm. Poster presentation at ACR/ARHP Annual Scientific Meeting; November 6-11, 2010; Atlanta, GA.
20. Engel-Nitz N, Burke J, Garris C, et al. Distinguishing levels of disease flare in patients with systemic lupus erythematosus using administrative claims data. Poster presentation at ACR/ARHP Annual Scientific Meeting; November 6- 11, 2010; Atlanta, GA.
21. Kan H, Song X, Bechtel B, et al. Resource utilization (HRU) and costs associated with flares in patients with systemic lupus erythematosus (SLE) in a U.S. Medicaid population. Poster presentation at ISPOR 17th Annual International Meeting; June 2-6, 2012; Washington, DC.
22. Heckman JJ, Ichimura H, Todd P. Matching as an econometric evaluation estimator: evidence from evaluating a job training programme. Rev Econ Stud. 1997;64:605-654 (Pubitemid 127466391)
23. Austin PC, Grootendorst P, Anderson MG. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med. 2007;26:734-753 (Pubitemid 46206593)
24. Ho DE, Imai K, King G, Stuart E. Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference. Pol Anal. 2007;15:199-236
25. Goetzel RZ, Hawkins K, Ozminkowski RJ, Wang S. The health and productivity cost burden of the top-10 physical and mental health conditions affecting six large US employers in 1999. J Occup Environ Med. 2003;45: 5-14 (Pubitemid 36091516)
26. Urowitz MB, Gladman DD, Ibanez D, et al. Evolution of disease burden over 5 years in a multicentre inception systemic lupus erythematosus cohort. Arthritis Care Res. 2012;64:132-137
27. Nossent J, Kiss E, Rozman B, et al. Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus. 2010;19: 949-956
28. Gladman DD, Urowitz MB, Rahman P, Ibanez D, Tam LS. Accrual of organ damage in patientswith systemic lupus erythematosus over time. J Rheumatol. 2003;30:1955-1959 (Pubitemid 37075543)
29. Lahita RG. Systemic Lupus Erythematosus. New York, NY: John Wiley & Sons; 1987
30. Laustrup H, Voss A, Green A, Junker P. SLE disease patterns in a Danish population-based lupus cohort: an 8-year prospective study. Lupus. 2010;19:239-246
31. Bujan S, Ordi-Ros J, Paredes J, et al. Contribution of the initial features of systemic lupus erythematosus to the clinical evolution and survival of a cohort of Mediterranean patients. Ann Rheum Dis. 2003;62:859-865 (Pubitemid 37026497)
32. Nossent JC. SLICC/ACR Damage Index in Afro-Caribbean patients with systemic lupus erythematosus: changes in and relationship to disease activity, corticosteroid therapy, and prognosis. J Rheumatol. 1998;25:654-659 (Pubitemid 28212371)
33. Helmick CG, Felson DT, Lawrence RC, et al. National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58:15-25
34. Campbell R, Cooper GS, Gilkeson GS. The impact of systemic lupus erythematosus on employment. J Rheumatol. 2009;36:2470-2475
35. Baker K, Pope J. Employment and work disability in systemic lupus erythematosus: a systematic review. Rheumatology. 2009;48:281-284
36. Scofield L, Reinlib L, Alarcon GS, Cooper GS. Employment and disability issues in systemic lupus erythematosus: a Review. Arthritis Rheum. 2008;59:1475-1479
37. Panopalis P, Yazdany J, Gillis JZ, et al. Health care costs and costs associated with changes in work productivity among persons with systemic lupus erythematosus. Arthritis Rheum. 2008;59:1788-1795
38. Huscher D, Merkesdal S, Thiele K, Zeidler H, Schneider M, Zink A; German Collaborative Arthritis Centres. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis. 2006;65:1175-1183 (Pubitemid 44277392)
39. Sutcliffe N, Clarke AE, Taylor R, Frost C, Isenberg DA. Total costs and predictors of costs in patients with systemic lupus erythematosus. Rheumatology. 2001;40:37-47